Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...
With home persisting as one of the weakest performing categories at Target stores during a most challenging fourth quarter, the 1,677-unit discount department store is reacting by reducing its shelf ...
The average one-year price target for Editas Medicine (NASDAQ:EDIT) has been revised to 13.68 / share. This is an increase of 5.56% from the prior estimate of 12.96 dated June 1, 2023. The price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback